$ISIS Up to date company activities and other impo
Post# of 94264
Posted On: 03/20/2014 6:07:48 PM
$ISIS Up to date company activities and other important information about $ISIS
$ISIS
DD Notes ~ http://www.ddnotesmaker.com/ISIS
##### recent news/filings ~ source: finance.yahoo.com
Thu, 20 Mar 2014 17:54:48 GMT ~ Nasdaq stocks posting largest percentage increases
- A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: InterCloud Systems rose 22.9 percent to $12.90. Bind Therapeutics rose 12.0 percent to $15.40. RiceBran Tech rose 10.6 percent ...
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Thu, 20 Mar 2014 17:05:57 GMT ~ Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
read full: http://www.fool.com/investing/general/2014/03...lnk0000001
*********************************************************
Wed, 19 Mar 2014 21:05:00 GMT ~ BioMed Realty Trust Leases Space To Life Science Firms
read full: http://news.investors.com/031914-693867-biome...;ven=yahoo
*********************************************************
Wed, 19 Mar 2014 11:05:48 GMT ~ Isis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
read full: http://finance.yahoo.com/news/isis-pharmaceut...48087.html
*********************************************************
Wed, 19 Mar 2014 11:00:00 GMT ~ Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
- CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3Rx, an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease. "ANGPTL3 is a genetically validated target. We know that humans who have loss-of-function mutations in ANGPTL3 exhibit lower levels of LDL-cholesterol and triglycerides and also display increased insulin sensitivity," said Sotirios Tsimikas, M.D., Professor of Medicine, Director of Vascular Medicine, University of California, San Diego. "Patients with dyslipidemia often have multiple cardiovascular and metabolic risk factors. As such, treating these patients can be challenging and involve multiple different treatment regimens. These patients would benefit tremendously from a drug that could provide benefit across multiple cardiovascular risk factors, like LDL-cholesterol and triglycerides, which are often too high despite currently available drugs."
read full: http://finance.yahoo.com/news/isis-pharmaceut...00376.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ISIS&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ISIS&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/ISIS/filings
Latest financials: http://www.otcmarkets.com/stock/ISIS/financials
Latest news: http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines
Major holdings: http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ISIS
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Isis+Pharmaceutica...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.isip.com
Alexa: http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.isip.com
Short Sales: http://www.otcmarkets.com/stock/ISIS/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ISIS/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ISIS/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ISIS+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ISIS+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet: http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow: http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ISIS
Bloomberg: http://www.bloomberg.com/quote/ISIS:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek: http://investing.businessweek.com/research/st...icker=ISIS
Barchart: http://www.barchart.com/quotes/stocks/ISIS
OTC Short Report: http://otcshortreport.com/index.php?index=ISIS
Investopedia: http://www.investopedia.com/markets/stocks/ISIS/?wa=0
http://www.pennystocktweets.com/stocks/profile/ISIS
##### last known share structure ~ source: otcmarkets.com
Market Value: $5,351,040,367 a/o Mar 19, 2014
Shares Outstanding: 117,270,225 a/o Feb 21, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/ISIS
$ISIS
DD Notes ~ http://www.ddnotesmaker.com/ISIS
##### recent news/filings ~ source: finance.yahoo.com
Thu, 20 Mar 2014 17:54:48 GMT ~ Nasdaq stocks posting largest percentage increases
- A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: InterCloud Systems rose 22.9 percent to $12.90. Bind Therapeutics rose 12.0 percent to $15.40. RiceBran Tech rose 10.6 percent ...
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Thu, 20 Mar 2014 17:05:57 GMT ~ Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
read full: http://www.fool.com/investing/general/2014/03...lnk0000001
*********************************************************
Wed, 19 Mar 2014 21:05:00 GMT ~ BioMed Realty Trust Leases Space To Life Science Firms
read full: http://news.investors.com/031914-693867-biome...;ven=yahoo
*********************************************************
Wed, 19 Mar 2014 11:05:48 GMT ~ Isis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
read full: http://finance.yahoo.com/news/isis-pharmaceut...48087.html
*********************************************************
Wed, 19 Mar 2014 11:00:00 GMT ~ Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
- CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3Rx, an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease. "ANGPTL3 is a genetically validated target. We know that humans who have loss-of-function mutations in ANGPTL3 exhibit lower levels of LDL-cholesterol and triglycerides and also display increased insulin sensitivity," said Sotirios Tsimikas, M.D., Professor of Medicine, Director of Vascular Medicine, University of California, San Diego. "Patients with dyslipidemia often have multiple cardiovascular and metabolic risk factors. As such, treating these patients can be challenging and involve multiple different treatment regimens. These patients would benefit tremendously from a drug that could provide benefit across multiple cardiovascular risk factors, like LDL-cholesterol and triglycerides, which are often too high despite currently available drugs."
read full: http://finance.yahoo.com/news/isis-pharmaceut...00376.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ISIS&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ISIS&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/ISIS/filings
Latest financials: http://www.otcmarkets.com/stock/ISIS/financials
Latest news: http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines
Major holdings: http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ISIS
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Isis+Pharmaceutica...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.isip.com
Alexa: http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.isip.com
Short Sales: http://www.otcmarkets.com/stock/ISIS/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ISIS/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ISIS/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ISIS+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ISIS+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet: http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow: http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ISIS
Bloomberg: http://www.bloomberg.com/quote/ISIS:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek: http://investing.businessweek.com/research/st...icker=ISIS
Barchart: http://www.barchart.com/quotes/stocks/ISIS
OTC Short Report: http://otcshortreport.com/index.php?index=ISIS
Investopedia: http://www.investopedia.com/markets/stocks/ISIS/?wa=0
http://www.pennystocktweets.com/stocks/profile/ISIS
##### last known share structure ~ source: otcmarkets.com
Market Value: $5,351,040,367 a/o Mar 19, 2014
Shares Outstanding: 117,270,225 a/o Feb 21, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/ISIS
(0)
(0)